Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05066672 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

A Phase 2 study, sponsored by Navitor Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
250
Enrollment target

NCT05066672: Completed Phase 2 study, sponsored by Navitor Pharmaceuticals.

NCT05066672 is a Phase 2 study that has completed, run by Navitor Pharmaceuticals. The registered enrollment target is 250 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05066672, a Phase 2 study, has completed, sponsored by Navitor Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target

Study Summary

This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

Primary Outcome

MADRS is a 10-item scale (Reported sadness, Apparent sadness, Inner tension, Reduced sleep, Reduced appetite, Concentration difficulties, Lassitude, Inability to feel, Pessimist thoughts, and Suicidal thoughts) where each item is scored from 0 to 6. The total score is the sum of the 10 items ranging from 0 to 60 where higher scores indicate more severe depression, and lower scores are better outcomes. A negative change from baseline indicates improvement in depressive symptoms.

Interventions

  • DRUG NV-5138
  • DRUG matched placebo

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2022-01-18
Est. Completion 2025-01-21
Phase Phase 2
Navitor Pharmaceuticals

3 total trials

What the finished NCT05066672 record still lists

NCT05066672 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% higher).

The record links to 0 conditions, and to 2 interventions - of which NV-5138 is the first listed.

NCT05066672 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05066672 about?

NCT05066672 is a clinical study titled "Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression". This study will evaluate the efficacy and safety of NV-5138 in adults with TRD

What is the current status of trial NCT05066672?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-01-18. Estimated completion is 2025-01-21.

What interventions are being tested in trial NCT05066672?

The interventions under investigation include: NV-5138 (DRUG), matched placebo (DRUG).

Who is sponsoring clinical trial NCT05066672?

This trial is sponsored by Navitor Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05066672's enrollment target sits among peer trials

250 222nd of 2000 higher than 1,768 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05066672, the US trial registry maintained by the National Library of Medicine. NCT05066672 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.